CR10684A - Metodos para administrar agentes hipoglicemicos de larga duracion - Google Patents

Metodos para administrar agentes hipoglicemicos de larga duracion

Info

Publication number
CR10684A
CR10684A CR10684A CR10684A CR10684A CR 10684 A CR10684 A CR 10684A CR 10684 A CR10684 A CR 10684A CR 10684 A CR10684 A CR 10684A CR 10684 A CR10684 A CR 10684A
Authority
CR
Costa Rica
Prior art keywords
hypoglycemic agents
methods
managing long
term hypoglycemic
term
Prior art date
Application number
CR10684A
Other languages
English (en)
Inventor
a bush Mark
E Matthews Jessica
e walker Susan
Original Assignee
Smithkline Beecham Corp
Koppert Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp, Koppert Bv filed Critical Smithkline Beecham Corp
Publication of CR10684A publication Critical patent/CR10684A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invencion se refiere a metodos y composiciones farmaceuticas relacionadas con administrar agentes hipoglicemicos y/o agonistas de GLP-1 en donde la media de los valores de concentracion maxima en el plasma (Cmax) y/o area bajo la curva (AUC) del agente hipogrlicemicos son incrementados y/o sostenidos.
CR10684A 2006-09-13 2009-03-23 Metodos para administrar agentes hipoglicemicos de larga duracion CR10684A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82547206P 2006-09-13 2006-09-13
US86839106P 2006-12-04 2006-12-04

Publications (1)

Publication Number Publication Date
CR10684A true CR10684A (es) 2009-04-28

Family

ID=39184534

Family Applications (1)

Application Number Title Priority Date Filing Date
CR10684A CR10684A (es) 2006-09-13 2009-03-23 Metodos para administrar agentes hipoglicemicos de larga duracion

Country Status (25)

Country Link
US (3) US8338369B2 (es)
EP (1) EP2073834B1 (es)
JP (2) JP5524620B2 (es)
KR (1) KR101472601B1 (es)
CN (1) CN103705911A (es)
AR (1) AR062775A1 (es)
AU (1) AU2007296499C1 (es)
BR (1) BRPI0716765A8 (es)
CA (1) CA2662622C (es)
CL (1) CL2007002634A1 (es)
CR (1) CR10684A (es)
EA (1) EA017159B1 (es)
ES (1) ES2442869T3 (es)
IL (1) IL197448A (es)
JO (1) JO2945B1 (es)
MA (1) MA30768B1 (es)
MX (1) MX2009002863A (es)
MY (1) MY149911A (es)
NO (1) NO20091266L (es)
NZ (1) NZ575419A (es)
PE (2) PE20080840A1 (es)
SG (2) SG174770A1 (es)
TW (1) TWI430806B (es)
WO (1) WO2008033888A2 (es)
ZA (1) ZA200901548B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1965823T1 (sl) 2005-11-04 2016-09-30 Glaxosmithkline Llc Corporation Service Company Postopki za dajanje hipoglikemičnih sredstev
PT2373681T (pt) * 2008-12-10 2017-04-11 Glaxosmithkline Llc Composições farmacêuticas de albiglutida
US8691763B2 (en) 2010-05-04 2014-04-08 Glaxosmithkline Llc Methods for treating or preventing cardiovascular disorders and providing cardiovascular protection
RS56998B1 (sr) 2010-12-16 2018-05-31 Novo Nordisk As Čvrste kompozicije koje sadrže agonist glp-1 i so n-(8-(2-hidroksibenzoil)amino)kaprilne kiseline
WO2012140117A1 (en) 2011-04-12 2012-10-18 Novo Nordisk A/S Double-acylated glp-1 derivatives
WO2013139694A1 (en) 2012-03-22 2013-09-26 Novo Nordisk A/S Compositions of glp-1 peptides and preparation thereof
HUE042757T2 (hu) 2012-03-22 2019-07-29 Novo Nordisk As Szállító szert tartalmazó készítmények és elõállításuk
WO2013189988A1 (en) 2012-06-20 2013-12-27 Novo Nordisk A/S Tablet formulation comprising a peptide and a delivery agent
US20160067184A1 (en) * 2013-05-02 2016-03-10 Novo Nordisk A/S Oral Dosing of GLP-1 Compounds
PT3004155T (pt) 2013-05-28 2021-12-22 Takeda Pharmaceuticals Co Composto peptídico
JP6995042B2 (ja) 2016-05-24 2022-02-04 武田薬品工業株式会社 ペプチド化合物
KR102647171B1 (ko) 2018-02-02 2024-03-15 노보 노르디스크 에이/에스 Glp-1 작용제 및 n-(8-(2-하이드록시벤조일)아미노)카프릴산의 염을 포함하는 고형 조성물
AR125086A1 (es) * 2021-03-23 2023-06-07 Lilly Co Eli Composiciones que contienen análogos de incretina y usos de estas

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5545618A (en) * 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
US5512549A (en) 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
ATE493998T1 (de) 1996-08-08 2011-01-15 Amylin Pharmaceuticals Inc Pharmazeutische zusammensetzung mit einem exendin-4-peptid
US6277819B1 (en) 1996-08-30 2001-08-21 Eli Lilly And Company Use of GLP-1 or analogs in treatment of myocardial infarction
US6380357B2 (en) 1997-12-16 2002-04-30 Eli Lilly And Company Glucagon-like peptide-1 crystals
JP2002523466A (ja) * 1998-08-28 2002-07-30 イーライ・リリー・アンド・カンパニー インスリン向性ペプチドの投与方法
EA003922B1 (ru) * 1999-05-17 2003-10-30 Конджачем, Инк. Продолжительно действующие инсулинотропные пептиды
US6395767B2 (en) * 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
CA2716959A1 (en) 2000-12-07 2002-06-13 Eli Lilly And Company Glp-1 fusion proteins
WO2002047716A2 (en) 2000-12-13 2002-06-20 Eli Lilly And Company Chronic treatment regimen using glucagon-like insulinotropic peptides
JP2005506956A (ja) * 2001-06-01 2005-03-10 イーライ・リリー・アンド・カンパニー 長時間作用性ｇｌｐ−１製剤
CA2458371A1 (en) * 2001-08-23 2003-03-06 Eli Lilly And Company Glucagon-like peptide-1 analogs
AR036711A1 (es) 2001-10-05 2004-09-29 Bayer Corp Peptidos que actuan como agonistas del receptor del glp-1 y como antagonistas del receptor del glucagon y sus metodos de uso farmacologico
YU31004A (sh) 2001-10-18 2006-08-17 Bristol-Myers Squibb Company Mimetici humanog glukagonu sličnog peptida-1 i njihova upotreba u lečenju dijabetesa i srodnih stanja
WO2003059934A2 (en) * 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin fusion proteins
ES2545090T3 (es) 2001-12-21 2015-09-08 Human Genome Sciences, Inc. Proteínas de fusión de albúmina y GCSF
EP1585959A4 (en) 2002-01-08 2007-11-14 Lilly Co Eli PEPTIDE-1 ANALOGUES OF EXTENSION GLUCAGON TYPE
EP1594530A4 (en) 2003-01-22 2006-10-11 Human Genome Sciences Inc HYBRID PROTEINS OF ALBUMIN
ES2524916T3 (es) * 2003-11-12 2014-12-15 Sino-Med International Alliance, Inc. Compuestos heterocíclicos de ácido borónico
JP4697596B2 (ja) * 2004-01-13 2011-06-08 旭硝子株式会社 多層積層体
HUE027902T2 (en) * 2004-02-09 2016-11-28 Human Genome Sciences Inc Corp Service Company Albumin fusion proteins
JP2008501765A (ja) * 2004-06-11 2008-01-24 ノボ　ノルディスク　アクティーゼルスカブ Ｇｌｐ−１アゴニストを用いた薬剤誘発性肥満の中和
SI1965823T1 (sl) * 2005-11-04 2016-09-30 Glaxosmithkline Llc Corporation Service Company Postopki za dajanje hipoglikemičnih sredstev
WO2007139589A1 (en) 2006-05-26 2007-12-06 Bristol-Myers Squibb Company Sustained release glp-1 receptor modulators

Also Published As

Publication number Publication date
JP2010503697A (ja) 2010-02-04
MX2009002863A (es) 2009-03-30
US20130005652A1 (en) 2013-01-03
BRPI0716765A2 (pt) 2013-09-24
IL197448A0 (en) 2011-08-01
AU2007296499B2 (en) 2013-05-02
ES2442869T3 (es) 2014-02-14
AU2007296499A1 (en) 2008-03-20
IL197448A (en) 2013-06-27
KR20090059155A (ko) 2009-06-10
US8338369B2 (en) 2012-12-25
JP5524620B2 (ja) 2014-06-18
US20140066371A1 (en) 2014-03-06
US20100009910A1 (en) 2010-01-14
TW200824706A (en) 2008-06-16
TWI430806B (zh) 2014-03-21
AU2007296499C1 (en) 2013-09-12
EP2073834A2 (en) 2009-07-01
BRPI0716765A8 (pt) 2017-02-21
JP5753924B2 (ja) 2015-07-22
NZ575419A (en) 2011-11-25
CA2662622C (en) 2017-01-17
JP2014148524A (ja) 2014-08-21
ZA200901548B (en) 2010-02-24
CN103705911A (zh) 2014-04-09
MA30768B1 (fr) 2009-10-01
CL2007002634A1 (es) 2008-05-16
WO2008033888A2 (en) 2008-03-20
EA200970274A1 (ru) 2009-08-28
AR062775A1 (es) 2008-12-03
SG10201501749WA (en) 2015-05-28
KR101472601B1 (ko) 2014-12-15
EP2073834B1 (en) 2013-10-23
JO2945B1 (en) 2016-03-15
PE20121528A1 (es) 2012-12-12
PE20080840A1 (es) 2008-08-27
EA017159B1 (ru) 2012-10-30
NO20091266L (no) 2009-06-09
MY149911A (en) 2013-10-31
WO2008033888A3 (en) 2008-10-16
SG174770A1 (en) 2011-10-28
EP2073834A4 (en) 2010-11-03
CA2662622A1 (en) 2008-03-20

Similar Documents

Publication Publication Date Title
CR10684A (es) Metodos para administrar agentes hipoglicemicos de larga duracion
AR115939A2 (es) Composición que contiene palmitoil-etanolamida ultra-micronizada
GT200600096A (es) Composicion farmaceutica para el tratamiento del cancer
ECSP088239A (es) Composición de liberación de fármaco sostenida
DOP2018000297A (es) Derivado de glucagon, conjugado del mismo, composición que comprende el mismo y uso terapéutico del mismo
GT201000008A (es) Agentes citotoxicos que comprenden nuevos derivados de tomaimicina y su uso terapeutico
BR112014016668A2 (pt) composições para cuidados pessoais contendo silicone iônico e agente formador de filme
ECSP109934A (es) Compuesto - 946
AR089931A1 (es) Composiciones farmaceuticas que contienen dimetilfumarato
PE20131324A1 (es) Formulacion subcutanea de anticuerpo anti-her2
AR088382A1 (es) Formulaciones de etanercept estabilizadas con xilitol
DOP2011000264A (es) Derivados de aminotetralina, composiciones farmaceuticas que los contienen y sus usos en terapia
CL2011002697A1 (es) Compuestos derivados de 3-[4-(oxo-dihidropiridin)bencil]-1,3-oxazin-ona hidratados, inhibidores 11beta-hsd1; composicion farmaceutica que los comprende; y su uso en el tratamiento de la diabetes
GT200700034A (es) Composiciones farmaceuticas de antagonistas del anticuerpo anti-cd40
UY36542A (es) Formulaciones farmacéuticas para anticuerpos anti-tnf-alfa
CL2012001583A1 (es) Preparación oftálmica que comprende: a) povidona yodada, b) un agente refrescante y c) uno o más entre alcanfor, borneol, lubricante, emoliente, antiinflamatorio esteroidal y antinflamatorio no esteroidal; y su uso para el tratamiento y/o profilaxis de un trastorno ocular o una infección.
ECSP088973A (es) Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3)
AR094548A1 (es) Dispersión sólida físicamente estable
CL2012002317A1 (es) Compuestos derivados de tienopirimidinas, inhibitores de quinasas mnk1/mnk2; composicion farmaceutica; y su uso para elt ratamiento o profilaxis de enfermedades metabolicas, tales como diabetes, daño renal, cancer, enfermedades inflamatorias, entre otras.
CO6491060A2 (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
CL2012002815A1 (es) Composicion para el cuidado bucal que comprende uno o mas compuesto de curcumina y una fuente de iones de zinc; correspondiente a 0.02 a 3% en peso de citrato de zinc; y uso de una fuente de iones de zinc para suprimir la degradacion y/o decoloracion del compuesto de curcumina en una composicion ara el cuidado bucal.
AR068845A1 (es) Composicion farmaceutica que contiene n-(3-metoxi-5-metilpirazin-2-il)-2-(4-((1,3,4-oxadiazol-2-il))fenil)piridin-3-sulfonamida util para el tratamiento del cancer
CR20120171A (es) Uso de n-(4-((3-(2-amino-4-pirimidinil)-2-piridinil)oxi) fenil)-4-(4-metil-2-tienil)-1-ftalazinamina en el tratamiento de cáncer resistente al agente antimitótico
NI201400122A (es) Agentes terapéuticos para administración subcutánea optimizados
CL2012003341A1 (es) Composicion farmaceutica de administracion oral que compende bendamustina o un ester, una sal o un solvato de la misma, y un excipiente que es un agente tensioactivo no ionico e hidrofilico; combinacion farmaceutica; y su uso para el tratamiento de leucemia linfocitica cronica y el mieloma multiple, entre otras enfermedades.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)